Patented, single source cancer drug prices remain unchanged under 30% margin cap, NPPA data shows
Summary
The findings raise questions about the extent to which the measure will bring down the cost of newer, patented cancer treatments.
Description from The Hindu.
Who is covering this
-
Patented, single source cancer drug prices remain unchanged under 30% margin cap, NPPA data shows
The findings raise questions about the extent to which the measure will bring down the cost of newer, patented cancer treatments.
